| Species Reactivity | Human; |
| Clone | Pasritamig |
| Source/Isotype | Human IgG1(L23A/L235A/D356E/L358M), Kappa |
| Application | / |
| Specificity | Detects KLK2&CD3 |
| Gene | KLK2&CD3 |
| Other Names | KLK2: KLK2A2, hGK-1, hK2 CD3: CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8 |
| Gene ID | KLK2: 3817 (human) CD3: 943 (human) |
| Background | Pasritamig is a bispecific monoclonal antibody drug targeting CD3 and Kallikrein 2(KLK2) , and its research background stems from the urgent need for more accurate and efficient therapies in the field of prostate cancer treatment. Traditional prostate cancer treatments such as surgery, radiotherapy and hormone therapy often face drug resistance in advanced patients. Although progress has been made in targeted therapy, there are still challenges in target selection. As a kallikrein family member, KLK2 is highly expressed on the surface of prostate cancer cells, but hardly expressed in normal tissues, which makes it an ideal tumor-specific target. PASRITAMIG combines CD3 receptor on the surface of T cells and KLK2 on the surface of tumor cells to form immune synapses, which can activate the killing effect of T cells on tumor cells and achieve precise and potent anti-tumor effects. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human; |
| Clone | Pasritamig |
| Source/Isotype | Human IgG1(L23A/L235A/D356E/L358M), Kappa |
| Application | / |
| Specificity | Detects KLK2&CD3 |
| Gene | KLK2&CD3 |
| Other Names | KLK2: KLK2A2, hGK-1, hK2 CD3: CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8 |
| Gene ID | KLK2: 3817 (human) CD3: 943 (human) |
| Background | Pasritamig is a bispecific monoclonal antibody drug targeting CD3 and Kallikrein 2(KLK2) , and its research background stems from the urgent need for more accurate and efficient therapies in the field of prostate cancer treatment. Traditional prostate cancer treatments such as surgery, radiotherapy and hormone therapy often face drug resistance in advanced patients. Although progress has been made in targeted therapy, there are still challenges in target selection. As a kallikrein family member, KLK2 is highly expressed on the surface of prostate cancer cells, but hardly expressed in normal tissues, which makes it an ideal tumor-specific target. PASRITAMIG combines CD3 receptor on the surface of T cells and KLK2 on the surface of tumor cells to form immune synapses, which can activate the killing effect of T cells on tumor cells and achieve precise and potent anti-tumor effects. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
